D&B Hoovers can help you create a more profitable relationship from prospect to client faster. Find key prospects and growth opportunities. D&B Hoovers, a sales acceleration solution, provides a faster path to prospect to profitable relationship through the use of data and analytics. B2B sales professionals can connect with customers faster to grow their businesses. Access detailed intelligence on over 120 million business records. Provide insight and intelligence into the tools that your marketers and sellers use every day. A user-friendly interface and automated workflow features, including triggers, alerts and smart lists, as well as intuitive search and conceptual search. D&B Hoovers combines Dun & Bradstreet's largest commercial database with sophisticated analytics to provide a rich sales intelligence solution. D&B Hoovers provides dynamic search and list-building capabilities as well as realtime trigger alerts, detailed company profiles and valuable research reports.
Learn more
Qualio is a purpose-built quality and compliance platform for life sciences companies operating in complex, high-stakes regulatory environments. Medical device, SaMD, biotech, and pharma teams use Qualio to replace fragmented eQMS tools, spreadsheets, and consultant-driven audits with a single, validated system that delivers continuous audit and inspection readiness.
Qualio combines a modern eQMS with Compliance Intelligence—an AI-driven layer that continuously evaluates how well real operating data aligns with regulatory requirements. Instead of treating audits as one-off events, teams gain always-on visibility into compliance coverage, risk exposure, and readiness across FDA, ISO, EU MDR, GxP, and software-intensive standards.
Core quality workflows—document control, training, CAPA, change management, supplier quality, and design controls—are directly connected to regulatory obligations and objective evidence. Deep integrations with Jira, Azure DevOps, GitHub, TestRail, and Salesforce automatically capture proof from development and operational systems, eliminating manual evidence gathering and reducing compliance drag on engineering teams.
Compliance Intelligence runs multi-standard gap analysis in under an hour, flags emerging risks before they become findings or 483s, and maps reusable evidence across frameworks to accelerate submissions and market expansion. All insights are explainable and traceable back to specific clauses and internal policies, supporting validation and audit expectations.
The result: audit readiness in weeks instead of months, fewer fire drills, faster launches, and lower long-term compliance cost. Qualio turns compliance from a reactive burden into a predictable, scalable system.
Learn more
Ovid
Each day, a diverse group of healthcare professionals including nurses, doctors, students, professors, and administrators turn to Ovid for the latest research, which encompasses contributions from more than 120 publishers and spans over 100 specialized fields. The New England Journal of Medicine (NEJM), recognized for its commitment to delivering exceptional research and vital information to clinical practice, serves as an invaluable resource for physicians by ensuring they remain current on advancements that affect their patients' care. A thorough peer-review and editing process is employed to assess manuscripts, guaranteeing their scientific validity, innovation, and significance. Available on Ovid®, NEJM showcases groundbreaking research, clinical perspectives, and medical advancements across more than 125 disciplines, all offered through a respected platform renowned for medical research. Additionally, the Ovid® Synthesis Clinical Evidence Manager provides a user-friendly cloud-based solution, boasting unmatched capabilities for literature search and review, further enhancing the research experience for healthcare professionals. This combination of resources empowers practitioners to stay informed and improves patient outcomes through evidence-based care.
Learn more
BenevolentAI
BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.
Learn more
